Twin Focus Capital Partners’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Twin Focus Capital Partners’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-1,088	Closed	-$50K	–	99
2015 Q3	$50K	Hold	1,088	–	–	0.06%	82
2015 Q2	$35K	Hold	1,088	–	–	0.04%	93
2015 Q1	$35K	Hold	1,088	–	–	0.03%	96
2014 Q4	$41K	Buy	+1,088	New	+$29.9K	0.05%	98

Other funds holding NAVB

Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Platinum Management New York $16.4M AUM 30.38% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Twin Focus Capital Partners's NAVB Position: Q4 2015 in Review

Twin Focus Capital Partners sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2015, closing a stake of 1,088 shares — an estimated $50K sold.

Twin Focus Capital Partners first reported a position in NAVB in Q4 2014 and held it in 4 quarters. The position peaked at $50K in Q3 2015. 78 funds tracked by Wall St. Rank hold NAVB as of Q4 2015.

Twin Focus Capital Partners reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2015 after selling out during the quarter.
Twin Focus Capital Partners sold 1,088 Navidea Biopharmaceuticals Inc. shares in Q4 2015, an estimated $50K.
Twin Focus Capital Partners first reported a position in Navidea Biopharmaceuticals Inc. in Q4 2014 and held it in 4 quarters.
Twin Focus Capital Partners's Navidea Biopharmaceuticals Inc. position peaked at $50K in Q3 2015.
78 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2015.

Based on Twin Focus Capital Partners's 13F filing for Q4 2015, filed 16 Feb 2016.